Physician profile
David Nelson
NPI 1386676526
$1,646.13
in general payments reported to CMS, 2019-2025
25 companies · $225 in 2025
The $225 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $555 · 2020: $125 · 2021: $11.16 · 2022: $343 · 2023: $271 · 2024: $116 · 2025: $225.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $612.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $611.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $220.18 | 2021-2025 | |
| Glaxosmithkline, LLC. | $177.73 | 2019-2025 | Shingrix, Arexvy, Bexsero |
| Boehringer Ingelheim Pharmaceuticals, INC. | $158.24 | 2019-2025 | Jardiance |
| Regeneron Healthcare Solutions, INC. | $137.17 | 2022-2023 | Dupixent |
| Merck Sharp & Dohme LLC | $122.80 | 2019-2020 | |
| Novo Nordisk INC | $117.70 | 2019-2025 | Wegovy |
| Lucid Diagnostics INC. | $112.87 | 2022 | |
| Janssen Pharmaceuticals, INC | $84.75 | 2019-2022 | |
| Pfizer INC. | $74.94 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $67.53 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $49.11 | 2022-2025 | Caplyta |
| Amgen INC. | $39.62 | 2019-2020 | |
| Astrazeneca Pharmaceuticals Lp | $36.39 | 2019-2020 | |
| Lilly USA, LLC | $34.13 | 2022-2023 | Trulicity, Mounjaro |
| Alkermes, INC. | $25.36 | 2023 | Aristada, Lybalvi |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Irhythm Technologies, INC. | $23.27 | 2023 | Zio Xt Patch |
| Inspire Medical Systems, INC. | $23.19 | 2024 | Inspire |
| Dynavax Technologies Corporation | $20.87 | 2019 | |
| Abbott Laboratories | $20.68 | 2025 | Freestyle Libre 3 |
| Lundbeck LLC | $20.24 | 2024 | Rexulti |
| Gilead Sciences, INC. | $18.65 | 2019 | |
| Strongbridge US INC. | $18.07 | 2019 | |
| Sobi, INC | $16.30 | 2023 | |
| Impel Pharmaceuticals INC. | $13.31 | 2023 | Trudhesa |
| Teva Pharmaceuticals USA, INC. | $13.03 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Nelson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.